Introduction
MDA (3,4-methylenedioxyamphetamine) and MDMA (3,4-methylenedioxymethamphetamine) are two of the most well-known members of the MDxx family of substituted amphetamines. Both produce empathogenic, stimulant, and mood-elevating effects, and both are Schedule I controlled substances in the United States and most countries worldwide. Despite their structural similarity -- MDMA is simply MDA with an added methyl group on the nitrogen atom -- the two compounds produce meaningfully different experiences, carry different risk profiles, and occupy different niches in both recreational and research contexts.
MDA is sometimes called "sass" or "sassafras" on the street, while MDMA is the active ingredient in ecstasy or molly. Critically, MDA is also an active metabolite of MDMA: when you take MDMA, your liver converts a portion of it into MDA via N-demethylation. This means every MDMA experience includes some MDA effects, which become more prominent at higher doses and during the tail end of the experience.
Understanding the differences between these two compounds is essential for anyone interested in harm reduction, pharmacology, or the evolving landscape of entactogen research.